TheraCryf PLC develops therapeutics for brain disorders, focusing on neuropsychiatry, particularly addiction and fatigue. Its lead program is an orexin-1 antagonist targeting binge eating disorder, while a second program involves a dopamine transporter antagonist aimed at fatigue related to conditions like multiple sclerosis. The company also collaborates with Erasmus Medical Centre on a grant-funded project for SFX-01, a treatment for glioblastoma. TheraCryf operates as a virtual biotech, outsourcing research and development while aiming to license its drug candidates to larger pharmaceutical companies after reaching proof-of-concept trials.